Melanoma: From Impossible to Treat to Poster Child for Targeted Therapies
An AJMC Panel Discussion
Challenges in Oncology Practice
Status in the States: In Louisiana, Will Privatization Affect Efforts to Stop Cancer?
Dual HER2 Blockade Less Effective in PI3KCA-Mutant Breast Cancer
European Cancer Congress 2013
Trebananib Shows Promise in Recurrent Platinum-Sensitive Ovarian Cancer
Pooled Analysis Reinforces Long-Term Survival Benefit With Ipilimumab
Positive Idelalisib Data End Late-Stage CLL Trial
New Approaches to Medicaid Expansion: Hybrid Plans Offer Alternatives for Covering More People
Safety Concerns Halt Ponatinib Development
First Generic Version of Capecitabine Gains FDA Approval
Volasertib Given Breakthrough Therapy Designation
Melanoma Combination Granted Priority Review Designation by FDA
In Historic Vote, FDA Backs Perjeta for Pre-surgical Breast Cancer Treatment
Ofatumumab Receives Breakthrough Therapy Designation for Earlier Use in CLL
